Abstract:A three-phase computational protocol for drug discovery has been developed that includes 1) 3D shape characterization of binding sites of a protein to predict optimum performance with selected molecular docking programs; 2) Implementation of predictive algorithms for pharmacokinetic properties and ADME profiling for targeted searches in the ZINC15 database; 3) Flexible molecular docking/dynamics protocols of small molecule/protein complexes for drug discovery. Focusing on cancer immunotherapy to implement this computational approach, the allosteric site of ecto-5’-nucleotidase (CD73), a regulator of the extracellular concentration of adenosine, is targeted for large scale small molecule searches. CD73 which hydrolyzes AMP to adenosine, is a GPI-anchored cell surface protein cleaved and activated in the extracellular environment as a homodimer. CD73 exhibits higher expression on lymphocytes, endothelial, and epithelial cells during a stress response and his been reported activated for various types of cancer. CD73 participates in blocking antitumor responses and enhances tumor growth and metastasis by producing high levels of adenosine in the extracellular environment. Protein coordinates of CD73 were downloaded for these from Rutgers Consortium of Structural Biology (RCSB) Protein Data Bank (PDB) and the potential inhibitory molecules from the ZINC15 Database. AutoDock Vina was selected as the ideal docking program for the target based on comparing predicting binding constants with actual Ki's and RMSD analysis of the co-crystallized ligand with the re-docked ligand. Once molecules with high affinity predicted scores were identified from docking, molecular dynamics studies were performed on the highest scoring protein/small molecule complexes. Studies were carried out using GROMACS, implemented with AMBER force field. Dissociation constants (Ki's) for the protein-ligand complex were calculated throughout MD runs. Conformational changes in the binding sites were observed visually and quantitified with PCA analysis. Novel hydrogen bonding networks and hydrophobic networks of residues in the 3D structures were identified to connect the active sites to the allosteric binding site using a MD protocol.

Allosteric Inhibition of the Guanine Nucleotide Exchange Factor DOCK5 by a Small Molecule

A Steric-inhibition model for regulation of nucleotide exchange via the Dock180 family of GEFs.

Insights into the biological functions of Dock family guanine nucleotide exchange factors

Structural basis for the dual GTPase specificity of the DOCK10 guanine nucleotide exchange factor

Dissociation mechanism of GDP from Cdc42 via DOCK9 revealed by molecular dynamics simulations.

Molecular dynamics simulations reveal the inhibition mechanism of Cdc42 by RhoGDI1

Small Molecule Targeting Cdc42-Intersectin Interaction Disrupts Golgi Organization and Suppresses Cell Motility

Automated NMR Fragment Based Screening Identified a Novel Interface Blocker to the LARG/RhoA Complex

Discovery of New Inhibitors of Cdc25B Phosphatases by Molecular Docking-Based Virtual Screening

A Novel Small Molecule Regulator of Guanine Nucleotide Exchange Activity of the ADP-ribosylation Factor and Golgi Membrane Trafficking*

Small-molecule allosteric inhibitors of GPX4

An SH3-binding allosteric modulator stabilizes the global conformation of the AML-associated Src-family kinase, Hck

Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q

Identification Of Allosteric Inhibitors Of Cd73 Using Three-Phrase Computational Protocol For Drug Discovery

Break CDK2/Cyclin E1 Interface Allosterically with Small Peptides

An integrated docking and molecular dynamics simulation approach to discover potential inhibitors of activin receptor-like kinase 1

Break CDK2/Cyclin E1 interface allosterically with small peptides.

Molecular mechanism of regulation of RhoA GTPase by phosphorylation of RhoGDI

Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2 WT and SHP2F285S by molecular dynamics study

Rational Design and Characterization of a Rac GTPase-specific Small Molecule Inhibitor.

L 2 The curious case of the inhibition of the p 90 ribosomal S 6 kinase by a plant flavonol glycoside , SL 0101